Surgical Innovation Associates Raises $15 Million In Oversubscribed Series B Round, Appoints Veteran Medtech Ceo

Dec 16, 2021•about 4 years ago

Amount Raised

$15 Million

Round Type

series b

Chicago

Description

Surgical Innovation Associates, Inc. (SIA), a growth-stage medical device company that manufacturers fully-resorbable, biosynthetic implants for the high-growth, multi-billion-dollar markets of plastic, reconstructive, and general surgery, today announced the successful close of its Series B round of financing.

Company Information

Company

Surgical Innovation Associates (Sia)

Location

Chicago, Illinois, United States

About

Founded in Chicago in 2016, SIA created the DuraSorb® product family and has led it from ideation through FDA 510k clearance, CE marking, and into the operating room. The company is based in Chicago, IL (USA) and DuraSorb is commercially available in the USA and Europe. Use of DuraSorb®, like any implantable medical device, carries risk of complications that may arise from the surgical implantation procedure or from the device itself. A full list of Warnings and Precautions is available in the Instructions for Use documents for US and EU surgeons. In the United States, the device has been cleared only for use in reinforcement of soft tissue where weakness exists, and remains investigational for specific applications in breast reconstruction and aesthetics. Learn more at sia.health.

Funding Insights

Based on industry data

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Surgical Innovation Associates Raises $15 Million In Oversubscribed Series B Round, Appoints Veteran Medtech Ceo

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Funding Insights

Company Information